
Moderna
OrganizationOn 2 shows in Health & Science this week · 1.6× usual · most on BioCentury This Week
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It develops RNA therapeutics, especially mRNA vaccines, using messenger RNA to instruct cells to produce proteins that can generate immune responses; its pipeline also includes programs targeting infectious diseases and cancer.
Rank this week
Share of the conversation
1.1‰ of what listeners heard
Reach this week
Tone this week
Not enough signal yet (fewer than 3 episodes scored).
Share of the conversation
Mentions of Moderna per 1,000 mentions of anything, 7-day rolling, health & science.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 3 | 0.23‰ | 1 |
| Oct 4 | 0.23‰ | 1 |
| Oct 8 | 0.45‰ | 1 |
| Oct 10 | 0.65‰ | 1 |
| Oct 12 | 0.68‰ | 1 |
| Oct 13 | 0.91‰ | 1 |
| Oct 16 | 1.38‰ | 3 |
| Oct 17 | 1.41‰ | 1 |
| Oct 23 | 1.29‰ | 5 |
| Oct 27 | 1.81‰ | 3 |
| Oct 30 | 1.72‰ | 4 |
| Nov 16 | 0.35‰ | 2 |
| Nov 17 | 0.67‰ | 2 |
Why is it trending?· Last 30 days
Moderna cancer-vaccine data, leaks and market reaction drive discussion
Moderna’s positive phase-three adjuvant melanoma cancer-vaccine data prompted extensive discussion across the shows, with Stephen Hansen on BioCentury This Week calling it a major biotech-market surprise.[1]
Breaking Biotech’s Matthew Cloutier highlighted results showing 82.2% two-year recurrence-free survival versus 70% and a 0.58 hazard ratio for the treatment group.
The shows also discussed leaked data and the resulting stock sell-off, while The Readout Loud described the results as positive but questioned why the stock fell.[2][3][4]
BioCentury This Week’s Lauren Martz said the melanoma results could support or caution against broader personalized cancer-vaccine investment, while noting the required effect size remains unknown.[5]
Sources · 5 moments
- 1.BioCentury This Week · Ep. 392 - Biotech markets: Pause before the storm?Stephen Hansen · Oct 13 · Listen at 2:53 ↗
“you know, didn't help. But, you know, I think what was, I don't know if ironic maybe is the right word to use here, but through the bigger damper on biotech was actually that there was a big surprise win that probably did more damage than s”
- 2.The Readout Loud · 419: Assessing Merck and Moderna's mRNA cancer vaccineElaine Chen · Oct 30 · Listen at 6:11 ↗
“The way that this data was released was actually a little bit unconventional. It was published by this oncology site. They broke the embargo on the data. And when that happened, Moderna stock plunged. So, you know, it sounds like the data a”
- 3.Breaking Biotech · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Matthew Cloutier · Oct 26 · Listen at 0:00 ↗
“Hello, everybody. Welcome to another episode of Breaking Biotech, another end-of-week wrap-up stream. I've got a lot to get into. There's certainly been a lot of news the last little while, so I've got a few stories to share, and we'll get”
- 4.Breaking Biotech · 119 - $IVA: Can Lanifibranor Deliver in Phase 3 MASH?Matthew Cloutier · Oct 23 · Listen at 0:57 ↗
“I'll try to get to one this weekend. I was going to talk about Moderna's data that was going to be released on Saturday, but it looks like the data leaked. So not going to be too much to talk about there, but we'll find some topics and we s”
- 5.BioCentury This Week · Ep. 394 - Security concerns in U.S., China reshaping biotechLauren Martz · Oct 27 · Listen at 27:48 ↗
“Well, so first I would say we don't know how large that effect size has to be. That's still an unknown at this point. But I think this could go either way. So Moderna and Merck went into melanoma as their first indication, which can be a go”
Written by AI from the cited moments; every quote is checked against the transcript.
Who is saying what about Moderna
Verified quotes from the last 90 days: who made the most claims, and which way they leaned.
- Matthew Cloutier16 claims on 1 show
“Most of the revenue, though, is due to the increase in international COVID vaccine sales.”
Breaking Biotech · Nov 9 ↗ - Jim Cramer9 claims on 1 show
“Moderna was a $63 stock. The next day, it closed above $174”
Mad Money w/ Jim Cramer · Nov 13 ↗ - John Coogan5 claims on 1 show
“the stock has been on this wild ride up and down, fueled by speculation that they cured cancer”
TBPN · Oct 23 ↗
27 more with Pro.
Discussed alongside
Names that come up in the same conversations as Moderna.
Embed this
Paste this on your site to show Moderna's current trend:
<iframe src="https://podlume.ai/embed/e/moderna" width="360" height="220" style="border:0" loading="lazy" title="Moderna on PodLume Trends"></iframe>